A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Hemostatic changes associated with recombinant human erythropoietin (rHu Epo) treatment
Alterações hemostáticas associadas ao tratamento com eritropoietina humana recombinante (rHu Epo)
Acta Médica Portuguesa
Alterações hemostáticas associadas ao tratamento com eritropoietina humana recombinante (rHu Epo)
End-stage chronic renal failure (CRF) is often associated with platelet' disfunction and therefore with impaired hemostasis. Several investigators have reported that rHu Epo, used in the treatment of CRF anaemia, is able to activate a broad spectrum of hematopoietic stem cells, and therefore is able to increase the number of platelets and to induce correction of platelet disfunction. In order to investigate hemostasis changes associated with rHu Epo we studied 8 dialysis patients before and 12
pmid:2048426
fatcat:xo2g6vfbsvhavkaprddypbql6q